An additional dose of canagliflozin 300 mg ( Treatment C ) , but not 150 mg ( Treatment D ) , prior to the MMTT on Day 3 provided greater postprandial PG reduction versus placebo ( difference in incremental glucose AUC0-2h , -7.5 % for B vs A ; -18.5 % for C vs A ; -12.0 % [ P = 0.012 ] for C vs B ) , leading to modestly greater reductions in total glucose AUC0-2h with Treatment C versus Treatment B or D. Canagliflozin was generally well tolerated .